Slide 1: Optomed Q2 2023
Optomed Q2 2023 4th August 2023 Seppo Kopsala, CEO Sakari Knuutti, CFO
Slide 2: Q2-2023 Highlights
Q2-2023 Highlights 1. 2. 3. Software segment Positive profitability Device sales under 4+ % growth track trend continues own brands increases, continued OEM decreases
Slide 3: Q2-2023 Key Figures
Q2-2023 Key Figures REVENUE WAS STABLE Q2/2023 Q2/2022 Change Revenue 3,744 3,733 0.3% Gross profit 1) 2,486 2,149 15.7% Gross margin 2) 66.4% 57.6% 8.8pps EBITDA -462 -813 43.1% EBITDA margin -12.4% -21.8% 9.4pps Net profit / loss -1,314 -1,328 1.1% Earnings per share -0.08 -0.10 13.0% Cash flow fr
Slide 4: H1-2023 Key Figures
H1-2023 Key Figures REVENUE GROWTH WAS DRIVEN BY OUR SOFTWARE SEGMENT THAT GREW 11.9% H1/2023 H1/2022 Change Revenue 7,222 6,947 4.0% Gross profit 1) 4,962 4,339 14.4% Gross margin 2) 68.7% 62.4% 6.3pps EBITDA -976 -1,750 44.2% EBITDA margin -13.5% -25.2% 11.7pps Net profit / loss -2,471 -2,698 8.4%
Slide 5: Segment highlights
Segment highlights OPT@MED
Slide 6: Devices Segment Q2-2023
Devices Segment Q2-2023 DEVICES’ REVENUE DECLINED DUE TO LACK OF MAJOR OEM ORDERS Q2/2023 Q2/2022 Change Revenue declined 6.5 % due to 1. lack of major OEM orders during the quarter Revenue 1,273 1,361 -6.5% Gross profit 674 642 5.0% Strong global distributor sales 2. performance continues - improve
Slide 7: Software Segment Q2-2023
Software Segment Q2-2023 POSITIVE TREND CONTINUES, BOTH REVENUE AND PROFITABILITY INCREASED Q2/2023 Q2/2022 Change Revenue increased by 4.2 %, 1. gross margin by almost 10% and EBITDA margin improved 3.2 Revenue 2,471 2,372 4.2% pps. The increase was driven by new Gross profit 1,812 1,507 20.2% 2. h
Slide 8: Cash Flow Q2-2023
Cash Flow Q2-2023 CASH FLOW FROM OPERATING ACTIVITIES IMPROVED Q2 2023 Q2 2022 Loss for the financial year -1,314 -1,328 Cash flows before change in net working capital -479 -369 • Net cash from operating activities was 468 negative Change in net working capital 52 -189 Cash flows before finance ite
Slide 9: New Business Model
New Business Model SIGNIFICANT RECURRING REVENUE OPPORTUNITY IN THE US Complete Solution Recurring Revenue Model Customer Benefits Newly established From product sales to Solution leased, not complete screening No initial investments reimbursement sold – enables solutions with diagnosis Only monthly
Slide 10: Optomed's mission is to prevent blindness by improving access to eye screening globally
Optomed’s mission is to prevent blindness by improving access to eye screening globally Bringing AI-integrated Expansion into new Opening new customer health screening to the geographical markets segments: primary care market
Slide 11: Appendix
Appendix
Slide 12: Devices Segment: Key Financials H1-2023
Devices Segment: Key Financials H1-2023 1-6/2023 1-6/2022 Change % Revenue 2,161 2,425 -10.9% Gross profit 1,233 1,283 -3.9% Gross margin 57.0% 52.9 % EBITDA -643 -963 33.2% EBITDA margin -29.8% -39.7 %
Slide 13: Software Segment: Key Financials H1-2023
Software Segment: Key Financials H1-2023 1-6/2023 1-6/2022 Change % Revenue 5,061 4,522 11.9% Gross profit 3,729 3,056 22.0% Gross margin 73.7% 67.6% EBITDA 1,368 898 52.2% EBITDA margin 27.0% 19.9%
Slide 14: Cash Flow: H1-2023
Cash Flow: H1-2023 1-6/2023 1-6/2022 Loss for the financial year -2,471 -2,698 Cash flows before change in net working capital -980 -1,273 Change in net working capital 105 50 Cash flows before finance items -875 -1,223 Cash flows from finance items -38 -442 Net cash from operating activities -913 -
Slide 15: Balance Sheet
Balance Sheet 30 June 2023 30 June 2022 • Equity ratio of 63.6 (61.5) ASSETS percent Goodwill 4,256 4,256 Development costs 7,200 7,115 Other intangible assets 1,918 2,215 • Total borrowings of EUR 4.8 Total intangible assets 13,374 13,586 (6.3) million Total tangible assets 769 664 Total non-curren